Oncology and Hematology
33-48 of 71
- MinuteCE®
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
0.75 program credits
Harry Yoon, MD
Jaffer Ajani, MD
Harry Yoon, MD
Jaffer Ajani, MD
- MinuteCE®
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
0.75 program creditsHarry Yoon, MD
Jaffer Ajani, MD
- MinuteCE®
Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
0.75 program creditsHarry Yoon, MD
Jaffer Ajani, MD
Harry Yoon, MD
Jaffer Ajani, MD
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Carey Anders, MD, FASCO
Sarah Sammons, MD
Carey Anders, MD, FASCO
Sarah Sammons, MD
Sarah Sammons, MD
- MinuteCE®
Leveraging Clinical Data: HER2-Targeted ADCs in Second-Line and Beyond MBC
1.00 program creditCarey Anders, MD, FASCO
- MinuteCE®
Sequencing Strategies for Second-Line and Beyond Treatment of HER2+ MBC
1.00 program creditSarah Sammons, MD
Carey Anders, MD, FASCO
Sarah Sammons, MD
